Offsite construction specialist Merit Health has been appointed by Piramal to deliver their new £30m Antibody Drug Conjugate manufacturing facility expansion project in Grangemouth
Piramal specialises in developing and manufacturing bio-conjugates, including Antibody Drug Conjugates. ADCs are currently used in targeted cancer treatment but have a wider potential for further applications.
To expand the facility, Merit Health will use its FLEXI POD® solution, a hybrid of traditional shell and core and offsite manufactured fit-out which is particularly suited to larger technical buildings such as biopharma facilities and hospitals.
The FLEXI POD® solution has a 75-80% offsite manufactured value and provides benefits in terms of plant space reduction and services distribution, whilst delivering enhanced technical performance and energy performance.
Reduction in carbon footprint creates overall cost benefits in terms of capital investment and ongoing revenue including maintenance and energy.
‘Offsite manufacturing for sustainability as well as productivity’
Tony Wells, chief executive officer at Merit Health, said: “We are delighted to be working on another important manufacturing facility expansion project, showing that the UK life sciences sector is on a significant and rapid growth trajectory.
“We understand that speed and cost-efficiency combined with minimised risk and successful ‘right first time’ validation are crucial for the timely development of such treatments. Our offsite offering was developed to support these imperatives meaning that critical therapies and products are in production and manufacturing significantly quicker than traditional methods of construction can offer.
“We are also proud to work with the Piramal team to eliminate scope 1 carbon emissions from the building design as well as scope 2&3 reduction through off-site manufacturing for sustainability as well as productivity.”
